Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market. Definitive Agreement provides details of the previously announced intent to co-develop COVAXIN™ for the US market. Ocugen and Bharat Biotech to share US commercialization profits. Ocugen to receive initial supply of COVAXIN™ doses from...
Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering Lexaria also announced the pricing of an underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of...
TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating...
Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg - Company secures next step to continue to build-out pipeline of assets. - University researchers developed a proprietary and orally active bacterial vaccine...
A little-known biotech is trying its hand at developing a coronavirus vaccine. Can it succeed? over the past year, Vaxart stock has soared over 1,250% because of its spot in the lucrative coronavirus vaccine race. Its stock performance even outpaced those of biotechs that have already brought their coronavirus vaccines to market, such as Moderna and...
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus Clinical efficacy demonstrated in Phase...
First up... obvious from November 2020 that Singapore was already heading towards a spike/Wave2. After so long, appears sthat the inevitable is happening, and projecting forwards, by end Feb or early March, the MACD histogram would be positive. Note that this has had happened to China, obvious int he MACD histograms since Octoboer 2020, through to December 2020...
Oil the biggest traded commodity globally by far and therefor best indicator to detect commodity price inflation imho. From Investopedia artikel Why Didn't Quantitative Easing Lead to Hyperinflation? the following snippet: "During the Great Recession banks still had bad loans and toxic assets on their balance sheets as a result of the housing bubble burst and...
Edesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy EDSA has received regulatory approval from the U.S. Food and Drug Administration (FDA) and Health Canada to add a sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of Acute Respiratory Distress Syndrome (ARDS) - the leading cause...
Have you been shorting this bull market wondering why you're not winning? I've been getting direct messages asking me when is it a good time to short or why when there is a reversal candle there is no follow through to the downside. Zooming out to the 2 day chart I think you can see why. We are in a massive uptrend channel since early last year right after the...
Hard not to notice the similarity in the parabolic run from this winter compared to 2019. I hadn't considered this fractal until I matching them up. Both bull runs come from the lower bands of the logarithmic growth curves to around the mid-band, with approximately a +250%. This would imply a 6-month long down-trend extending to a 50% correction. Therefore...
My view on RUBBEREX are: 1) Weekly Stoch is on a bullish reversal 2) Price is currently testing on a support level 3) My presumption that the price will go to the next major support at 2.030. But I will look to take out my profit at 6% from my entry price (1.670) 4) Average EPS 5) Financial report looks impressive
AditxtScore™ Immune Monitoring Service Will be Operational on February 1st Company Plans to Offer Service through Channel Partners The initial application of the platform will be AditxtScore™ for COVID-19 which has been designed to provide a more complete assessment of an individual’s infection and immunity status with respect to the SARS-CoV-2 virus. We’re...
Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19 announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). The submission of the IND to FDA followed a Pre-IND meeting with FDA in which FDA gave specific...
GILD - The Sleeping Giant - Trend Reversal ___________________ ENTRY = 56.56 Double Bottom - +64 confirmation 1st Target = .236fib@72.33 2nd Target = .382fib@82.08 3rd Target = .5fib@89.97 HOLD Target = .618@97.85+ JAN22 Call Leaps Still...
As posted weeks to months ago, it is becoming clearer than daylight that Wave 2 is upon us in 2021. As described previously, the CONFIRMNED charts here have a peciliarity... that the MACD histograms hint of the trend months ahead in advance. As observable, Singapore is currently maanging pretty well, but is heading towards a Wave 2 slowly and surely. The trend...
My opinion on YONGTAI. 1) My "bullseye" target will be in Zone 2 2) Price between 0.255 to a minimum of 0.230 3) Yongtai is expected to bring in China Vaccination by the third quarter of this year. 4) They are still waiting for MOH NPRA approval to import vaccines from Shenzen Kangtai Biology. 5) Zone 2 in my opinion still the best zone to put your money...
APT - Here We Are Again BUYZONE = 10-12 1st Target = .236@14 2nd Target = .382@16 3rd Target = .5-.618 18/20 HODL Target = .786@22 ______________________________________________________________________________________________________________________ This content is for informational and educational purposes only. This is not in any way, shape or form financial...